The Neuro-Cells® platform focusses on neurodegenerative diseases for which no effective treatments exist.

​

Neuroplast obtained a European Orphan Disease Designation for the treatment of Traumatic Spinal Cord Injury with Neuro-Cells®, enabling fast track development. Traumatic Spinal Cord Injury is the first targeted therapeutic area, for which an international placebo-controlled phase II-III clinical trial is currently ongoing.

 

Based on the Neuro-Cells® platform, additional preclinical evidence has been obtained that suggests wider applicability for other conditions such as Frontotemporal Dementia and Traumatic Brain Injury.